Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial ...
Vergent Bioscience completed patient enrollment for its Phase 2 VISUALIZE trial, testing abenacianine for injection (VGT-309) in lung cancer surgery. The trial aims to improve tumor visibility during minimally invasive surgeries, with 89 patients enrolled across the U.S. and Australia. Positive results could lead to a Phase 3 study and a new drug application.
Related Clinical Trials
Reference News
Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial ...
Vergent Bioscience completed patient enrollment for its Phase 2 VISUALIZE trial, testing abenacianine for injection (VGT-309) in lung cancer surgery. The trial aims to improve tumor visibility during minimally invasive surgeries, with 89 patients enrolled across the U.S. and Australia. Positive results could lead to a Phase 3 study and a new drug application.